EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSATEG00000021460
Gene Symbol: PIK3R3
3 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSATEG00000004096
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSATEG00000010968
Gene Symbol: PIK3R5
4 Cross references
184 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSATEG00000018016
Gene Symbol: PIK3R2
3 Cross references
190 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSATEG00000016596
Gene Symbol: PLA2G7
2 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSATEG00000017677
Gene Symbol: GART
2 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSATEG00000022051
Gene Symbol: PLG
3 Cross references
255 Possible Orthologues:

Plasminogen Activator, Tissue

Ensembl ID : ENSATEG00000020915
Gene Symbol: PLAT
2 Cross references
207 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Alpha Polypeptide

Ensembl ID : ENSATEG00000014902
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSATEG00000008565
Gene Symbol: PDGFRB
3 Cross references
199 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 1

Ensembl ID : ENSATEG00000010457
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSATEG00000017409
Gene Symbol: PARP2
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).